Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Neoadjuvant Chemoradiotherapy for Rectal Cancer
NCT02031939Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2014
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in rectal cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 5 years. Started Jan 2014; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02031939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031939.